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Background: Placental growth factor (PlGF) and soluble-fms-like tyrosine kinase 1 (sFlt-1) 
are biomarkers of placental function used to aid diagnosis and prediction of pregnancy 
complications. This work verified the analytical performance of both biomarkers and provides 
preliminary diagnostic accuracy data to identify adverse pregnancy outcome in women with 
reduced fetal movement (RFM). 
 
Methods: Verification of sFlt-1 and PlGF assays included a comparative accuracy assessment 
of 24 serum samples analysed at six different sites, and laboratory specific precision estimates. 
The sFlt-1/PlGF ratio was assessed in serum samples obtained prospectively from 295 women 
with RFM ≥36 weeks’ gestation; diagnostic accuracy was evaluated using 2x2 tables and Area 
Under the Receiver Operator Characteristic (AUROC) curve. 
 
Results: Regression analysis showed performance between sites was good with Passing-
Bablok slopes ranging from 0.96 to 1.05 (sFlt-1) and 0.93 to 1.08 (PlGF). All sites had a mean 
bias <15% although there was poorer agreement at the lowest PlGF concentrations. All within 
and between batch coefficients of variation were <10%. In 289 women with an appropriately 
grown fetus, a sFlt-1/PlGF ratio ≥38 had a sensitivity of 0.20 (95% confidence interval [CI] 
0.07, 0.41), specificity of 0.88 (95% CI 0.83, 0.92) and AUROC curve of 0.58 (95% CI 0.47, 
0.68) to identify adverse pregnancy outcome.  
 
Conclusions: Analytical performance of the sFlt-1 and PlGF assays was comparable across 
different sites. The sensitivity of sFlt-1/PlGF to identify adverse pregnancy outcome in women 
with RFM was considered acceptable, in the absence of other tests, to progress to a pilot 




Placental growth factor (PlGF) and soluble fms-like tyrosine kinase-1 (sFlt-1) are proteins 
present in maternal circulation that hold significant promise as biomarkers to aid the diagnosis 
and management of pregnancy complications, particularly those that relate to placental 
dysfunction.1-5 Research evaluating these biomarkers initially focused on detection and 
management of preeclampsia4 but more recent studies suggest they have potential value in 
identifying other complications including: prediction of small for gestational age (SGA) 
infants,5, 6 fetal compromise after maternal presentation with reduced fetal movement (RFM)7 
and the need for intervention during labour, and compromise at the time of birth.8 A systematic 
review of diagnostic test accuracy (DTA) studies found that PlGF was the most accurate 
biochemical test to identify pregnancies that would end in stillbirth with a diagnostic odds ratio 
of 49.2 (95% confidence interval [CI] 12.7, 191), however this information comes from 5,894 
individuals, of whom only 16 had a stillbirth.9 While this is an important avenue of exploration 
to prevent stillbirth, further studies are needed to increase understanding of test accuracy of 
PlGF in the prediction of adverse pregnancy outcome. 
 
Measurement of sFlt-1 and PlGF utilises immunoassays, the majority of which are automated. 
While there are a number of reports describing the diagnostic accuracy of these tests in a variety 
of clinical settings,3, 5, 10-12 descriptions of method performance are relatively limited. It is 
important to conduct such studies since the utility of these assays in clinical practice depends 
upon reproducible, accurate analysis. In addition, introduction of protocols using common 
thresholds requires an understanding of how analytical methods compare between laboratories. 
PlGF is bound in maternal blood by sFlt-1 and assays measure either unbound PlGF or the ratio 
of sFlt-1 to PlGF with the latter performing as well as, or better than, each biomarker alone in 
the diagnosis of preeclampsia.3, 13, 14 Results for the Elecsys® sFlt-1 and Elecsys® PlGF 
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immunoassays (Roche Diagnostics; Germany) are comparable across a number of sites15 and 
similar analytical performance of these biomarkers has been demonstrated using other 
platforms including BRAHMS® Kryptor (ThermoFisher Scientific; Germany),16 Alere 
Triage® PlGF test (Alere Inc; USA), DELFIA® Xpress PlGF 1-2-3 test (PerkinElmer; 
Finland) and ELISA (R&D Systems; USA).17, 18 However, the methods have undergone further 
refinement and there is limited information regarding current performance including 
susceptibility to biotin interference which is a potential issue for some immunoassay systems.19-
21 
 
To understand method robustness in a wider clinical and laboratory context, we conducted a 
verification of analytical performance for the Elecsys® sFlt-1 and Elecsys® PlGF assays across 
sites participating in the ReMIT-2 trial.22 This is a multicentre, randomised controlled, 
interventional pilot trial investigating whether including measurement of the sFlt-1/PlGF ratio 
following maternal presentation with RFM ≥36 weeks’ gestation with the aim of preventing 
adverse pregnancy outcome is feasible. This population was chosen for this study because RFM 
is associated with increased risk of adverse pregnancy outcomes and placental dysfunction,23-
25 but management strategies based upon ultrasound scanning and induction of labour for RFM 
in all cases are associated with increased rates of obstetric intervention.26 Our prior data 
indicating improved test performance with inclusion of PlGF assessment would potentially 
allow intervention to be focussed on women with RFM who were more likely to benefit from 
early induction.7 Here we report the performance of sFlt-1 and PlGF across six UK laboratory 
sites and assess potential confounding pre-analytical factors including temperature stability and 
biotin interference. In addition, preliminary DTA data in this clinical context are presented, the 
objective of which was to evaluate the diagnostic accuracy of the sFlt-1/PlGF ratio in 
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identifying a composite adverse pregnancy outcome in women presenting with RFM ≥36 
weeks’ gestation. 
 
Materials and Methods 
Preparation, Distribution and Analysis of Samples 
Blood samples were collected by venepuncture into clot activator gel tubes (Sarstedt; 
Nümbrecht, Germany), centrifuged at 3000 g for 10 min, and the resultant serum split into 
aliquots and stored at -80⁰C. Frozen samples were sent on dry ice by same day courier and 
stored at -800C at the receiving site until required. Sites were instructed to thaw samples 
immediately prior to analysis. All samples were analysed using the Elecsys® sFlt-1 and 
Elecsys® PlGF fully automated immunoassays on three different models of Roche Cobas® 
analyser (801, 602 and e411; Roche Diagnostics; Mannheim, Germany). Assays were run 
according to manufacturer’s instructions and the sFlt-1/PlGF ratio was calculated for all 
samples. 
 
Verification of sFlt-1 and PlGF Analytical Performance 
Currently, there are no international reference materials to provide traceability of calibration 
of sFlt-1 or PlGF which contributes to a lack of gold standard analytical techniques to assess 
the accuracy of methods. Therefore, relative accuracy was addressed using anonymised 
residual serum blood samples routinely received in the Clinical Biochemistry Laboratory at the 
Royal Preston Hospital. For the study, 24 anonymised patient serum samples were distributed 
for analysis across six ReMIT-2 trial sites (Royal Preston Hospital, John Radcliffe Hospital, 
Sunderland Royal Hospital, St George’s Hospital, Royal Liverpool University Hospital and 
University Hospital of North Tees). The means of sFlt-1 and PlGF results for each sample were 
calculated and comparisons performed using Passing-Bablok regression analysis against the 
6 
 
mean as a target. Additionally, the percent bias was determined for each site using the mean as 
the comparator. The clinical impact of any bias seen between sites was assessed by comparing 
the sFlt-1/PlGF ratios obtained from each sample against published thresholds for pre-
eclampsia3, 10, 27 with the mean value use as the comparator. These thresholds have been adapted 
for clinical use by the authors as follows: the risk of developing pre-eclampsia is considered 
low with a sFlt-1/PlGF ratio <38 (i.e. can be ruled-out for 1 week), intermediate with a ratio 
≥38 to <85 (i.e. can be ruled-in within the next 4 weeks) and high with a ratio ≥85 (i.e. is a 
confirmed diagnosis).  
 
Within batch precision was determined on the 801 analyser at one site (Royal Preston Hospital) 
using three serum samples (n = 10). Between batch precision was assessed using two levels of 
internal quality control (IQC) materials (PreciControl Multimarker, Roche Diagnostics; 
Mannheim, Germany) on the Cobas® analyser at all eight ReMIT-2 sites (Manchester Royal 
Infirmary and James Cook University Hospital in addition to those listed above). Between 
batch precision data was collected to reflect real live usage over a time period to reach n = 20.  
The timeframe was dependent on the numbers done at each site and varied between three weeks 
and three months. For both assays, the lower limit of quantitation (LLOQ) was defined as the 
lowest measureable concentration with an acceptable precision and was assessed by analysing 
three low concentration samples in 10 separate runs. For both precision and LLOQ studies the 
mean, standard deviation (SD) and coefficient of variation (CV) were calculated. 
 
The stability of sFlt-1 and PlGF was tested in five serum samples at room temperature over 
24h, at 4°C over 4 weeks, at -20°C over 6 months and over 3 freeze thaw cycles. Biotin 
interference in the sFlt-1 and PlGF assays was determined at concentrations of 30, 60 and 500 
ng/mL biotin. These were chosen to reflect serum biotin concentrations which might occur 
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following ingestion of over-the-counter supplements or in patients taking mega doses for 
treating progressive Multiple Sclerosis.21, 28 Two serum pools were spiked with increasing 
doses of biotin (Sigma-Aldrich; Gillingham, UK) according to methods described previously.29 
Working solutions were made up in distilled water and the spiked amount was no more than 
5% of the total serum volume. Additionally, distilled water was spiked as a control sample to 
account for dilutional or matrix effects. The mean percentage difference between the control 
sample and the spiked serum pools were then calculated. 
 
Diagnostic Test Accuracy Study 
A preliminary DTA study was conducted to evaluate the sFlt-1/PlGF ratio (as the index test) 
for identifying adverse pregnancy outcome using maternal serum samples previously collected 
in three consecutive, separate studies run in a single tertiary UK maternity unit.7, 30 Each of 
these had ethics approval for measurement of placental analytes (FEMINA Oldham Research 
Ethics Committee [REC] reference 08/H1011/83, recruitment took place from August 2009 – 
October 2019; FEMINA2 Greater Manchester West REC reference 11/NW/0650, recruitment 
took place from January 2012 – May 2014; FEMINA3 Greater Manchester East REC reference 
16/NW/0481, recruitment started in August 2016 and is still ongoing) and written consent was 
obtained from all participants. Relevant eligibility criteria included women with a viable 
singleton pregnancy presenting with a primary complaint of maternal perception of RFM ≥36 
weeks’ gestation and having had an ultrasound scan for fetal biometry, liquor volume and 
umbilical artery Doppler on presentation. Exclusion criteria included maternal age <18 years 
and fetus with a known congenital abnormality. Samples were analysed at site 6 using a 
Cobas® e411 and as this took place after birth, clinical care was not influenced by the 




Clinical and demographic details were collected from participants at presentation, along with 
ultrasound scan results for fetal biometry, liquor volume and umbilical artery Doppler. 
Delivery and pregnancy outcomes included gestational age at delivery, birthweight and gender. 
The target condition was a composite adverse pregnancy outcome defined as birthweight <5th 
centile (derived from individualised birth weight centiles31), neonatal intensive care unit 
(NICU) admission, umbilical artery pH <7.1 at birth or stillbirth/neonatal death. Admission to 
NICU was regarded as any admission within the neonatal period regardless of indication. 
Where umbilical artery pH was missing it was assumed to be normal since this would not be 
measured in normal healthy babies. The reference standards were each of the four individual 
components of the composite outcome. Since stillbirth alone as a measure of adverse pregnancy 
outcome would require a very large number of participants, a composite outcome was used 
similar to those employed in other perinatal trials.32, 33 As sFlt-1 and PlGF were not measured 
until after birth, the clinicians determining whether the reference standard was present were 
not aware of the index test results. Similarly, those measuring the index test were unaware of 
whether the reference standard was present. 
 
We aimed to include 410 participants in the DTA study to achieve a margin of error of 10% 
for sensitivity and 2.3% for specificity assuming that the prevalence of adverse pregnancy 
outcome would be 10%, sensitivity of the sFlt-1/PlGF ratio would be 80% and specificity 
would be 95%. The diagnostic accuracy of sFlt-1, PlGF and the sFlt-1/PlGF ratio was 
calculated using Stata Version 15 (StataCorp, College Station, USA). Performance of the sFlt-
1/PlGF ratio was assessed using predefined levels of 38 (determined to be the optimal level to 
diagnose preeclampsia3) and 112 (95th centile value >37 weeks’ gestation). The diagnostic 
accuracy of currently used tests including estimated fetal weight (EFW) <10th centile, and 
oligohydramnios (defined by gestation-specific centile for amniotic fluid index or maximal 
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pool depth) as well as EFW <10th centile or sFlt-1/PlGF ratio ≥38 were also examined. 
Sensitivity, specificity, and positive and negative predictive values were calculated along with 
the Area Under the Receiver Operator Characteristic (AUROC) curve for the sFlt-1/PlGF ratio; 
95% CIs were calculated for test performance characteristics. Any instances of indeterminate 
or missing sFlt-1/PlGF ratios, or where all components for the adverse pregnancy outcome 
were indeterminate or missing, were excluded from the analysis. 
 
Results 
Verification of sFlt-1 and PlGF Analytical Performance 
Results for sFlt-1, PlGF and the sFlt-1/PlGF ratio from 24 samples analysed at each site were 
compared using Passing-Bablok analysis with the mean of all sites as the comparator. For all 
sites and assays, this gave slopes ranging from 0.89 to 1.08 and intercepts ranging from -6.52 
to 9.13 pg/mL (Table 1). In addition, percent bias for sFlt-1, PlGF and the sFlt-1/PlGF ratio 
from each site was plotted against the mean of all results which showed that for both 
biomarkers, most sites had a mean bias of <10% (Figure 1). The only exception was laboratory 
6 which had a mean bias for PlGF of -10.2% (Figure 1b), primarily due to greater variability 
at concentrations below 25 pg/mL when bias values ranged from -56 to 24% (Figure 1b). The 
variability at low PlGF concentrations impacted on the bias of the calculated sFlt-1/PlGF ratio; 
however over 70% of the sFlt-1/PlGF ratio results had a bias <10% (Figure 1c). Assessment of 
the clinical impact of this bias performed on individual sFlt-1/PlGF ratio results (n = 144) 
indicated that two samples (1.4%) would have been classified as having an intermediate risk 
of developing pre-eclampsia where the consensus mean was low risk. 
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Table 1: Passing-Bablok slope and intercept results for sFlt-1, PlGF and sFlt-1/PlGF ratio at 
each site  






























































































CI: confidence interval; PlGF: placental growth factor; sFlt-1: soluble fms-like tyrosine kinase-1 
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Within batch precision CVs for sFlt-1 were 1.13%, 0.53% and 0.63% at 82.1 pg/mL, 1020.6 
pg/mL and 13393.1 pg/mL respectively (n = 10). Within batch precision CVs for PlGF were 
1.20%, 0.69% and 1.04% at 14.5 pg/mL, 143.9 pg/mL and 1319.3 pg/mL respectively (n = 10).  
Between batch precision estimates were generally <5% at both levels of IQC material, mean 
CVs for all eight sites being 4.6% (Low QC) and 4.9% (High QC) for sFlt-1 along with 4.2% 
(Low QC) and 4.3% (High QC) for PlGF (Table 2). Precision estimates at one site with the 
e411 analyser were much higher (>20% for sFlt-1 and around 10% for PlGF) although this was 
not instrument type related as precision at other sites with the e411 analyser was <5% for both 
biomarkers at the concentrations assessed. 
 
The individual site percent bias is plotted against the mean of all sites for: (a) sFlt-1; (b) PlGF; (c) sFlt-
1/PlGF ratio. PlGF: placental growth factor; sFlt-1: soluble fms-like tyrosine kinase-1 
   Site 1 (801 Cobas® analyser);  Site 2 (602 Cobas® analyser);  Site 3 (e411 Cobas® analyser);  
x Site 4 (801 Cobas® analyser); - Site 5 (602 Cobas® analyser);  Site 6 (e411 Cobas® analyser).    
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Low QC High QC 
Mean (SD) %CV Mean (SD) %CV 
sFlt-1  
(n = 20) 
Site 1 (801) 98.1 (2.6) 2.7 959.9 (8.6) 0.9 
Site 2 (602) 110.7 (3.2) 2.9 994.3 (40.7) 4.1 
Site 3 (e411) 102.0 (21.9) 21.4 941.9 (200.7) 21.3 
Site 4 (801) 105.4 (1.8) 1.7 959.6 (40.8) 4.3 
Site 5 (602) 107.2 (1.1) 1.1 979.9 (8.8) 0.9 
Site 6 (e411) 99.1 (3.4) 3.4 986.1 (29.4) 3.0 
Site 7 (e411) 105.5 (2.0) 1.9 1020.7 (20.7) 2.0 
Site 8a (801) 104.6 (1.9) 1.8 938.6 (24.4) 2.6 
PlGF  
(n = 20) 
Site 1 (801) 108.4 (5.6) 5.2 1062.7 (54.3) 5.1 
Site 2 (602) 86.4 (3.9) 4.8 953.9 (33.4) 3.5 
Site 3 (e411) 87.5 (8.0) 9.2 936.7 (95.0) 10.1 
Site 4 (801) 86.5 (4.9) 5.6 888.9 (48.1) 5.4 
Site 5 (602) 84.7 (0.8) 1.0 939.2 (8.2) 0.9 
Site 6 (e411) 99.2 (2.6) 2.6 1072.2 (53.2) 5.0 
Site 7 (e411) 104.5 (1.7) 1.7 1041.7 (18.0) 1.7 
Site 8b (801) 86.6 (2.7) 3.1 930.0 (26.4) 2.8 
an = 9 for sFlt-1 low QC; n = 8 for sFlt-1 high QC.  
bn = 7 for PlGF low QC; n = 10 for PlGF high QC. 
CV: coefficient of variation; PlGF: placental growth factor; QC: quality control; SD: standard deviation; 




For the PlGF LLOQ, mean concentrations analysed were 5.2 pg/mL, 8.9 pg/mL and 10.7 
pg/mL which gave CVs of 9.05%, 4.31% and 6.24% respectively.  The LLOQ studies for sFlt-1 
were performed at mean concentrations of 12.1 pg/mL, 13.3 pg/mL and 21.5 pg/mL which 
resulted in CVs of 7.60%, 4.24% and 4.92% respectively. 
 
sFlt-1 and PlGF were demonstrated to be stable in serum when stored at -20⁰C for 6 months 
(Figure 2a), when stored at 4⁰C for 14 days (Figure 2b), and when stored at room temperature 
for 24h (Figure 2c). All serum samples tested had a mean difference from baseline of <10%. 
Additionally, both sFlt-1 and PlGF were stable over 3 freeze thaw cycles (Figure 2d). 
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Figure 2: Stability of sFlt-1 and PlGF in serum over various timeframes (n = 5) 
 
 
Stability of sFlt-1 and PlGF: (a) at -200C over 6 months; (b) at 40C over 14 days; (c) at room 
temperature over 24h; (d) over 3 freeze thaw cycles.  sFlt-1;     PlGF; error bars are 95% confidence 
intervals 
PlGF: placental growth factor; sFlt-1: soluble fms-like tyrosine kinase-1 
 
Addition of biotin to  pooled serum samples resulted in a reduction of >10% from the spiked 
control sample in the PlGF assay at biotin concentrations of 30, 60 and 500 ng/mL 
(Supplementary Figure 1). The effect was related to the concentration of biotin, with 500 
ng/mL resulting in a greater than -80% difference. With sFlt-1, interference was not as 
significant with biotin concentrations of 30 and 60 ng/mL having <10% bias (Supplementary 






Diagnostic Test Accuracy Study 
Across the three studies, samples from 423 participants were analysed (Supplementary Figure 
2). Three hundred and eighteen participants met the relevant inclusion criteria for the DTA 
study (≥36 weeks’ gestation). Twenty three were excluded due to the EFW being <10th centile 
at presentation (i.e. the fetus already had a diagnosis of being SGA) since this would be an 
indication for delivery after 37 weeks’ gestation and therefore not meet the inclusion criteria 
for ReMIT-222 and a further 6 had insufficient serum to conduct assays for both biomarkers 
which gave 289 participants with both sFlt-1 and PlGF results to calculate the ratio of both 
biomarkers. Maternal characteristics at baseline for all 318 participants are shown in 
Supplementary Table 1, the mean age of participants was 29.2 years (standard deviation [SD] 
5.5), mean body mass index (BMI) was 26.4 (SD 5.4) and just over half (54%) were in their 
first pregnancy. 
 
In 295 participants presenting with RFM ≥36 weeks’ gestation whose babies were ≥10th EFW 
centile, 26 (8.8%) had the target condition (composite adverse pregnancy outcome); 2.4% had 
a birthweight <5th centile, 4.1% were admitted to NICU, 3.7% had an umbilical artery pH <7.1 
at birth, and there were no stillbirths/neonatal deaths. Three babies had both low pH and NICU 
admission and one further baby had birthweight <5th centile and NICU admission. In babies 
who were ≥10th EFW centile and had results for both biomarkers (n = 289), the sFlt-1/PlGF 
ratio at a threshold of ≥38 had a sensitivity of 0.20 (95% CI 0.07, 0.41) and a specificity of 
0.88 (95% CI 0.83, 0.92) to predict the composite adverse pregnancy outcome (Table 3). 
Applying a threshold of ≥112 for the sFlt-1/PlGF ratio had a sensitivity of 0.04 (95% CI 0.00, 
0.20) with a specificity of 0.99 (95% CI 0.97, 1.00) (Table 3). The AUROC curve of the sFlt-
1/PlGF ratio to identify adverse pregnancy outcomes in these women was 0.58 (95% CI 0.47, 
0.68; Figure 3). For comparison, ultrasound EFW <10th centile alone (n = 318) had a sensitivity 
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of 0.24 (95% CI 0.11, 0.41) and a specificity of 0.95 (95% CI 0.91, 0.97), isolated 
oligohydramnios (n = 295) had a sensitivity of 0.12 (95% CI 0.02, 0.30) and a specificity of 
0.85 (95% CI 0.80, 0.89) and either EFW <10th centile or sFlt-1/PlGF ≥38 (n = 312) had a 
sensitivity of 0.39 (95% CI 0.23, 0.58) and a specificity of 0.83 (95% CI 0.78, 0.87; Table 3) 
to predict the composite adverse pregnancy outcome. No significant adverse events occurred 
as a result of taking the blood sample to perform the sFlt-1/PlGF test, or from measuring the 






























(0.87, 0.94) Negative 26 269 
Oligohydramnios in babies with 
EFW ≥10th centile (n = 295) 







(0.87, 0.94) Negative 23 228 
Umbilical artery PI >95th centile in 
babies with EFW ≥10th centile  
(n = 295) 







(0.87, 0.94) Negative 25 255 
sFlt-1/PlGF ≥38 in babies with 
EFW ≥10th centile (n = 289a) 







(0.88, 0.95) Negative 20 232 
sFlt-1/PlGF ≥112 in babies with 
EFW ≥10th centile (n = 289a) 







(0.88, 0.95) Negative 24 261 
EFW <10th centile or sFlt-1/PlGF 
≥38 (n = 312a) 







(0.88, 0.95) Negative 20 232 
aUnable to calculate sFlt-1/PlGF ratio for 6 cases due to missing sFlt-1 result (n = 3) or PlGF result (n = 3), one of whom had an adverse pregnancy outcome. 




Figure 3: Receiver Operator Characteristic curve for sFlt-1/PlGF ratio to predict composite 
adverse pregnancy outcome  
 
AUROC 0.58 (95% CI 0.47, 0.68).  
AUROC: area under receiver operator characteristic; CI: confidence interval; PlGF: placental growth 
factor; sFlt-1: soluble fms-like tyrosine kinase-1 
 
Discussion 
The potential for biomarkers of placental function to help detect pregnancy complications and 
aid diagnosis is an area of clinical practice that is regaining momentum after a period of initial 
study in the 1970s and 1980s. The majority of recent work has focused on the role of PlGF or 
the sFlt-1/PlGF ratio in the diagnosis of preeclampsia which has led to the National Institute 
for Health Care and Excellence (NICE) issuing guidance on the use of these biomarkers in 
suspected preeclampsia.34 As preeclampsia has its origins in placental dysfunction there is also 
interest in utilising placentally-derived biomarkers such as PlGF for other conditions related to 
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poor placental function e.g. fetal growth restriction or pregnancies that are likely to end in 
stillbirth6 or fetal and neonatal compromise resulting from labour.8 
 
Although there are various methods available to quantify sFlt-1 and PlGF, NICE guidance for 
preeclampsia specifically supports use of the Elecsys® sFlt-1 and Elecsys® PlGF assays 
(Roche Diagnostics; Germany).34 Therefore, we chose to use the Elecsys® system in this work 
and assessed test reproducibility of both assays across six different sites. There are currently 
no defined or published acceptance criteria for these biomarkers based on biological variability, 
but we consider the performance reported here acceptable across most of the concentration 
range tested. Performance of the PlGF assay at concentrations <25 pg/mL was more variable 
and caution is advisable when interpreting results at this lower limit. This may be due to these 
values being at the very lowest PlGF concentrations of a very wide analytical range (3-10,000 
pg/mL, limit of quantification 10 pg/mL) with a potentially greater impact of calibration curve 
fitting models. However, the absolute differences were small and are all below PlGF 
concentrations that should raise concerns in clinical practice, for example, NICE suggest a 
threshold of 100 pg/mL to define abnormality34 in the context of preeclampsia. If a ratio 
approach is used, there is potential to increase its variability in the instances where PlGF 
concentrations are below 25 pg/mL and this also need to be considered in interpretation. 
However, when the individual sFlt-1/PlGF ratios obtained by the six sites in this study were 
compared to pre-eclampsia diagnosis thresholds, <2% would have changed classification. This 
suggested that the variable performance at low concentrations of PlGF described here would 
not have a major effect on clinical outcomes. 
 
Between batch precision was acceptable for both assays with the mean CV assessed at eight 
sites being <5%. However, one outlier was noted at site 3 which had significantly higher 
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imprecision, in particular for sFlt-1, than the other sites. Most of the sites were in the method 
verification stage of using these biomarkers and therefore the observed precision at site 3 may 
have been compromised by either inconsistent handling of IQC materials or inexperience in 
using the assays. The most experienced laboratory (site 6) had noted that IQC performance 
decreased following initial opening of the bottle, even when it was kept refrigerated, and their 
standard practice changed to freezing aliquots of IQC material which improved observed 
precision. Further evaluation of sFlt-1 and PlGF stability in IQC materials is needed, 
particularly as the instability noted is inconsistent with the performance of these biomarkers in 
serum samples. This observation also highlights the need for development of independent third 
party IQC materials. Additionally, the clinical impact of bias and imprecision for these markers 
needs further consideration and this should be explored as external quality assessment schemes 
develop. Precision studies show that both sFlt-1 and PlGF assays can be acceptably quantitated 
down to the lowest concentrations tested with %CVs less than 10. We report acceptable 
precision and therefore a LLOQ at 12.1 pg/mL for sFlt-1 and 5.2 pg/mL for PlGF which 
highlights an improvement in the levels stated in the manufacturer’s product sheets (15 pg/mL 
and 10 pg/mL respectively). 
 
Both biomarkers also showed stability across a range of storage conditions and timeframes. 
This was an important consideration for samples collected in the ReMIT-2 trial since they are 
stored at -200C or lower for a maximum of 6 months prior to central analysis of sFlt-1 and 
PlGF which is being conducted as a confirmatory measure of reliability.22 Biotin interference 
with the sFlt-1 assay was limited at lower concentrations, but a greater effect was seen with the 
PlGF assay at 60 ng/mL. Both assays showed a much larger difference with biotin at a higher 
concentration of 500 ng/mL. Pregnancy multivitamin tablets taken once daily contain around 
50-150 µg of biotin so it is unlikely that pregnant women using such products will have blood 
22 
 
concentrations high enough to interfere with the sFlt-1 and PlGF assays. However, biotin is 
available as a single vitamin supplement at doses up to 10 mg once per day and this much 
higher concentration could potentially cause issues with accurate measurement of both 
biomarkers.  
 
These analytical performance findings agree with previously published manufacturer’s data15 
and have provided reassurance that the sFlt-1 and PlGF results generated in the ReMIT-2 trial 
and other multicentre clinical evaluations will be robust. This is particularly important since 
there is currently no External Quality Assessment scheme available in the UK for sFlt-1. It is 
therefore advisable to conduct similar analytical performance and stability research alongside 
any future trials using these biomarkers. In addition, the potential issue of biotin interference 
should be given due consideration in any research using the Elecsys® sFlt-1 and Elecsys® 
PlGF assays. 
 
For the DTA study, although the sensitivity of the sFlt-1/PlGF ratio ≥38 to detect an adverse 
pregnancy outcome in women with RFM was modest and lower than that used to diagnose 
preeclampsia, it was comparable to, or better than, other methods currently used in clinical 
practice following maternal presentation with RFM e.g. ultrasound fetal biometry, liquor 
volume and umbilical artery Doppler >95th centile (Table 3). The combination of EFW <10th 
centile or sFlt-1/PlGF ratio ≥38 was included for comparison and did improve sensitivity 
however, as EFW <10th centile would be an indication for immediate delivery, this would not 
meet the inclusion criteria for the ReMIT-2 trial.22 Using a threshold of ≥112 for the sFlt-
1/PlGF ratio did not improve prognostic performance. In common with analysis of the whole 
FEMINA2 dataset, addition of PlGF measurement improved the sensitivity to detect adverse 
pregnancy outcome above use of ultrasound alone.7 Importantly, views on this level of 
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sensitivity and specificity were sought from a patient and public involvement group (personal 
communication) and the independent Trial Steering Committee. These groups agreed that the 
increased sensitivity of adding sFlt-1/PlGF testing to currently available regimes without a 
significant reduction in specificity would aid the clinical management of women at risk of an 
adverse pregnancy outcome, and was therefore deemed an appropriate test to investigate further 
in a pilot trial. This opinion was strengthened by the fact that, in the absence of the sFlt-1/PlGF 
test, women with RFM would be randomised to continue with normal care in their pregnancy.22 
 
The AUROC curve observed in this study of 0.58 indicates that the sFlt-1/PlGF ratio is slightly 
better than chance to discriminate between women with and without composite adverse 
pregnancy outcomes. Overall, our findings for the sFlt-1/PlGF ratio are in agreement with other 
analyses which suggest PlGF measurement modestly improves the detection of adverse 
pregnancy outcome although this may differ for specific adverse outcomes. Analysis of a 
cohort of 3,953 participants found a combination of EFW, PlGF and uterine artery Doppler 
pulsatility index had a sensitivity of 0.63 for SGA births.35 In contrast, a combination of EFW 
and sFlt-1 had a sensitivity of 0.15 for emergency Caesarean section for fetal compromise 
during labour, and adverse outcomes after birth (low pH, Apgar score ≤7 at 5 min, NICU 
admission) were not predicted by any single or combination of measurements or biochemical 
or biophysical predictors.35 Our recent systematic review of DTA studies found that PlGF had 
the best predictive accuracy for identifying a pregnancy that ends in stillbirth, but that its 
performance was not as good as EFW alone in prediction of a SGA infant.9 Therefore further 
studies are needed to determine which biomarkers most accurately identify fetal and neonatal 





The current study limitations relate to sample size for both laboratory comparisons and 
diagnostic accuracy and the unblinded nature of the ultrasound scan findings. For the latter 
issue, this means that clinicians are aware of the results for EFW or abnormal liquor volume 
and umbilical artery Doppler which may lead to intervention thereby avoiding a potential 
adverse pregnancy outcome and confounding the observed diagnostic performance of these 
tests. Although restricted by sample size the laboratory study represents real world data from 
routine diagnostic laboratories and is the first data we are aware of showing how these methods 
perform across multiple sites in this setting. The planned sample size for the DTA study was 
not met meaning that the confidence intervals for the sensitivity and specificity of the 
sFlt-1/PlGF ratio to identify adverse pregnancy outcomes were slightly wider than planned. In 
addition, although modest improvements using the sF1t-1/PlGF ratio were observed in this 
study, the confidence intervals for the sensitivity and specificity overlapped with the other tests 
meaning a larger sample size would be required to identify whether the sF1t-1/PlGF ratio is 
better than the other tests. To address this the FEMINA3 trial is ongoing, and additional 
samples for DTA studies will also be obtained from the control arm of the ReMIT-2 trial.22 
Importantly, future clinical studies also need to address the impact of ethnicity, BMI and 
presence of co-morbidities on the test performance of the sFlt-1/PlGF ratio. 
 
The DTA study is strengthened as samples were obtained from a single tertiary UK maternity 
unit serving a population with a diverse demographic and ethnic background, plus eligibility 
criteria were kept simple to give a degree of generalisability. In addition, the investigators 
determining the index test and those determining the reference standard were blinded to each 
other’s results. Furthermore, this DTA analysis reports similar findings to a study using PlGF 
alone (rather than the sFlt-1/PlGF ratio) in low-risk pregnancies predicting fetal or neonatal 
25 
 
compromise, with AUROCs between 0.51 and 0.67 for different definitions of fetal and 
neonatal compromise .36  
 
To the best of our knowledge, this is the first report of sFlt-1/PlGF DTA results in women with 
RFM in late pregnancy and is a pragmatic initial exploration of test characteristics for these 
assays in this population. Knowledge of test characteristics and technical variation is 
particularly important when applying a threshold to initiate management or treatment as small 
changes in absolute values can modify the ratio. The sFlt-1/PlGF threshold of ≥38 is being 
assessed further in the ongoing ReMIT-2 pilot trial to identify adverse pregnancy outcome in 
women with RFM, the results of which will help determine whether a much larger trial using 
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